Displaying drugs 326 - 350 of 8040 in total
Chromium nicotinate
Approved
Experimental
Upadacitinib
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated ... [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients ... (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of …
Pyrantel
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis .
Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Description: … Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm ... Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of ... Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and …
Methadone
Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a...
Approved
Matched Description: … , and a long duration of action. ... Provision of OAT is often combined with education about harm reduction including use of clean needles ... The intention of substitution of illicit opioids with the long-acting opioids used in OAT is to prevent …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Vildagliptin
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia. ... [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- …
Rimegepant
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …
Rezafungin
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and ... L45633]
Clinical studies have shown that rezafungin is non-inferior to caspofungin for the treatment of …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …
Degarelix
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of …
Edetic acid
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Propiolactone
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, …
Metreleptin
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia,...
Approved
Matched Description: … of adipose tissue. ... [L41315] Administration of metreleptin results in improvement of metabolic symptoms including improvements ... of leptin deficiency in people with lipodystrophy. …
Moxidectin
Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of...
Approved
Investigational
Vet approved
Matched Description: … It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of ... Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side …
Diroximel fumarate
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Description: … of both North America and Europe. ... More than 80% of patients suffering from this disease have relapsing-remitting MS. ... Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … RET RTK inhibitors for the treatment of RET-driven cancers. ... , [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of ... [A202049, A202055, L15986]
Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is …
Lovastatin
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid...
Approved
Investigational
Matched Description: … studies to significantly reduce the risk of development of CVD and all-cause mortality. ... and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes ... [A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Description: … Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies ... genetics on the clearance of this drug [L2002]. ... It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of ... the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Loracarbef
Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Displaying drugs 326 - 350 of 8040 in total